About Salubris Biotherapeutics
Salubris Biotherapeutics is a Healthcare company based in Gaithersburg (United States) founded in 2016 by John Li. Antibody therapeutics are developed for cancer, cardiovascular, and metabolic diseases. Salubris Biotherapeutics has raised $35 million across 1 funding round. The company has 1 employees. Its chief executive, as recorded, is John Li. Salubris Biotherapeutics offers products and services including Antibody Therapeutics and Protein-Based Therapeutics. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Salubris.
Company details
Salubris Biotherapeutics was founded in 2016 in Gaithersburg, United States, as a biotechnology firm affiliated with Shenzhen Salubris Pharmaceuticals. Antibody and protein-based therapeutics are developed by the company for cancer, cardiovascular, and metabolic diseases. The lead candidate remains undisclosed and is in the preclinical stage, targeted at cancer treatment. Operations focus on advancing these biologics through research and development in the biopharmaceutical sector.
- Headquarters Gaithersburg, United States
- Employees 1
- Founders John Li
- SectorsHealthcare
- Email••••••••
- Website salubrisbio.com
- Social LinkedIn
- Legal Name Salubris
- Total Equity Funding$35M (USD)
in 1 rounds
- Latest Funding Round$35M (USD), Series A
Apr 2024
- Employee Count1
Products & Services of Salubris Biotherapeutics
Salubris Biotherapeutics offers a comprehensive portfolio of products and services, including Antibody Therapeutics and Protein-Based Therapeutics.
Develops treatments targeting cardiovascular diseases.
Advances therapies for oncology and cancer needs.
Funding Insights of Salubris Biotherapeutics
Salubris Biotherapeutics has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series A round of $35 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35M
- Total Rounds 1
- Last Round Series A — $35M
- First Round $35M
(Apr 2024)
All 1 funding rounds of Salubris Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $35M | Series A | – | – | – |
People of Salubris Biotherapeutics
16 people are tracked at Salubris Biotherapeutics (12 in leadership, 4 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
John Li | Founder & CEO | Leadership |
Naimish Pandya | Senior Vice President & Head Of Oncology | Leadership |
Shalabh Singhal | Chief Medical Officer | Leadership |
Ping Feng | Vice President | Leadership |
Sam Murphy | CEO | Leadership |
Michael Carrell | Senior Director, CMC | Leadership |
Alice Drumheller | Vice President Clinical Operations | Leadership |
Stephen Dipalma | Interim CFO | Leadership |
Jijun Dong | Chief Scientific Officer | Leadership |
Binyam Bezabeh | Director | Leadership |
Alida Simon | Human Resources Director | Leadership |
Jinhua (Jenny） Feng | Vice President, Head of CMC | Leadership |
Neal Salomon | Medical Lead | Team |
Amanda McEwen | Svp, Clinical Development | Team |
Alexander (Alex) Gelfand | Operations Manager | Team |
Ashleigh Chasteen | Senior Clinical Trial Manager | Team |
Complete people profiles for Salubris Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Salubris Biotherapeutics
2 dated milestones of Salubris Biotherapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Salubris Biotherapeutics is founded.
- Funding First funding round of $35.0M.
Web traffic of Salubris Biotherapeutics
The website of Salubris Biotherapeutics (salubrisbio.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 24.4% vs previous month
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Salubris Biotherapeutics (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Salubris Biotherapeutics
Complete news archive for Salubris Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Salubris Biotherapeutics
Salubris Biotherapeutics was founded in 2016 and raised its 1st funding round 8 years after it was founded.
Salubris Biotherapeutics is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
John Li is the CEO of Salubris Biotherapeutics, as recorded in our data. They have also founded this company.
Salubris Biotherapeutics is a funded company, having raised a total of $35M across 1 funding round to date. The company's 1st funding round was a Series A of $35M, raised on Apr 2024.
Salubris Biotherapeutics has 1 employees.
Salubris Biotherapeutics was founded in 2016 in Gaithersburg, United States, as a biotechnology firm affiliated with Shenzhen Salubris Pharmaceuticals. Antibody and protein-based therapeutics are developed by the company for cancer, cardiovascular, and metabolic diseases. The lead candidate remains undisclosed and is in the preclinical stage, targeted at cancer treatment. Operations focus on advancing these biologics through research and development in the biopharmaceutical sector.
Salubris Biotherapeutics offers Antibody Therapeutics and Protein-Based Therapeutics.
Salubris Biotherapeutics operates through Salubris.